2014
DOI: 10.1016/j.imbio.2013.08.005
|View full text |Cite
|
Sign up to set email alerts
|

IGKC and FcγR genotypes and humoral immunity to HER2 in breast cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
18
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 22 publications
(18 citation statements)
references
References 17 publications
0
18
0
Order By: Relevance
“…Anti-tumor marker specific antibodies may be detectable in cancer patients which indicate the role of humoral immunity in tumor destruction 22 . The anti-tumor activity of monoclonal antibodies has shown clinical success in treatment of different kinds of cancers 1,23-25 , but high concentrations of these reagents and their immunogenicity of repeatedly administration reveals the necessity of applying a suitable immunogenic agent for raising active immunity 26,27 .…”
Section: Discussionmentioning
confidence: 99%
“…Anti-tumor marker specific antibodies may be detectable in cancer patients which indicate the role of humoral immunity in tumor destruction 22 . The anti-tumor activity of monoclonal antibodies has shown clinical success in treatment of different kinds of cancers 1,23-25 , but high concentrations of these reagents and their immunogenicity of repeatedly administration reveals the necessity of applying a suitable immunogenic agent for raising active immunity 26,27 .…”
Section: Discussionmentioning
confidence: 99%
“…The KM 1,3 alleles were previously determined (Pandey et al, 2014), by a PCR-RFLP method (Moxley and Gibbs, 1992). …”
Section: Methodsmentioning
confidence: 99%
“…However, this effect has not been further confirmed in subsequent larger cohorts, compromising the predictive value of this polymorphism on trastuzumab resistance [95,97]. In fact, FCGR2A-131 H/H genotype has only demonstrated influence on antibody responsiveness to HER2 in determinate ethnicities (Table 5) [96,98].…”
Section: Tumor Host Factorsmentioning
confidence: 99%